About Immune Pharmaceuticals
Dr. Daniel Teper
Byline BIO: Dr. Daniel Teper is an authority on new drug treatments for diseases from cancers to rare autoimmune disorders, and on the global pharmaceutical and biotech industries. He is founder, CEO and Chairman of IMMUNE Pharmaceuticals, which he grew in three years to a NASDAQ listed company. Learn more at www.IMMUNEPharmaceuticals.com.
Broadcast BIO: Our guest today is an expert on new drug treatments for diseases that have long vexed humanity. Dr. Daniel Teper grew his company, IMMUNE Pharmaceuticals, into a NASDAQ listed firm in just three years while shuttling between Tel Aviv and New York. For more information, visit www.IMMUNEPharmaceuticals.com.
Full BIO: Dr. Daniel Teper is an authority on new drug treatments for diseases from cancers to rare autoimmune disorders. A 30-year veteran of the global pharmaceutical and biotech industries, he is founder, CEO and Chairman of IMMUNE Pharmaceuticals. He grew the company into a NASDAQ listed firm in just three years while shuttling between Tel Aviv and New York. Dr. Teper previously served as Managing Director for North America at Bionest Partners, a global strategy consulting firm advising pharmaceutical and public biotechnology companies. He has held senior executive positions in Europe, including Head of Commercial Operations for Glaxo France, President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi), and President at Global EURO RSCG Healthcare Worldwide, a leading marketing and communication group, and as Cofounder of Novagali. A native of Paris, Dr. Teper holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD. He and his wife Nicole have three sons and have been married 30 years. His passions, in addition to developing new drug treatments and companies, include tennis, wine and food. Learn more at www.IMMUNEPharmaceuticals.com.
Dr. Karin Hehenberger
Byline BIO: Karin Hehenberger, M.D., Ph.D., is Senior Vice President, Medical Affairs and Corporate Communications for IMMUNE Pharmaceuticals. The fast-growing company is developing new drugs to fight cancer and inflammatory diseases. Learn more at www.IMMUNEPharmaceuticals.com.
Broadcast BIO: Our guest knows what it is like to face chronic illness as a patient and doctor. Dr. Karin Hehenberger (SAY Hen-in-burger) underwent kidney and pancreas transplants at an early age. She is Senior Vice President, Medical Affairs and Corporate Communications at IMMUNE Pharmaceuticals. Dr. Hehenberger founded an organization called Lyfebulb, to help others facing chronic illnesses.
FULL BIO: Karin Hehenberger, M.D., Ph.D., is Senior Vice President, Medical Affairs and Corporate Communications for IMMUNE Pharmaceuticals. The fast-growing company is developing new drugs to fight cancer and inflammatory diseases. Dr. Hehenberger is responsible for managing the company’s relationships with medical opinion leaders and patient organizations, in addition to being part of the team handling media and investors. She has more than 15 years experience in the life sciences industry. She previously served as Executive Vice President, Scientific Affairs and Chief Medical Officer at Coronado BioSciences. She has held senior leadership positions at the Juvenile Diabetes Research Diabetes Foundation (JDRF), at Johnson & Johnson, Eyetech Pharmaceuticals and at public and private investment funds. She started her career at McKinsey & Co, and received her M.D. and Ph.D. degrees form the Karolinska Institute (Sweden). She also completed a post-doctorate at Harvard Medical School. Dr. Hehenberger is founder of Lyfebulb, an educational and social platform dedicated to helping those with chronic illnesses lead their optimal lifestyles. Diagnosed with type 1 diabetes at an early age, she has dedicated her life to helping others impacted by chronic illnesses. Her personal history with diabetes as well as its consequences, which required kidney and pancreas transplants, provide her with an understanding from a patient perspective as well as a medical professional. She has provided expert advice to top media outlets including Good Morning America Health, Fox News, Bloomberg Businessweek, Forbes, and NY 1. For more information, visit www.IMMUNEPharmaceuticals.com.
IMMUNE Pharmaceuticals, Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis and crohn’s disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. IMMUNE licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive worldwide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development Arm of AstraZeneca. IMMUNE’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, Crolibulin, a small molecule in Phase II in collaboration with the National Cancer Institute, and Amiket™, a Neuropathic Pain drug candidate ready for Phase III. Amiket has received Orphan Drug Designation for Post Herpetic Neuralgia. For more information, visit www.IMMUNEPharmaceuticals.com.